linjc16/ctgov huggingface dataset:
Global Electrical Heterogeneity and Clinical Outcomes

Study Overview
=================
Brief Summary
-----------------
This retrospective multicenter cohort will validate an independent association of electrocardiographic (ECG) global electrical heterogeneity (GEH) measures with sustained ventricular tachyarrhythmias and appropriate ICD therapies in systolic heart failure patients with primary prevention ICD, and will validate and re-calibrate GEH ECG risk score for prediction of sustained ventricular tachyarrhythmias and appropriate ICD therapies in systolic heart failure patients with primary prevention ICD.

Official Title
-----------------
Global Electrical Heterogeneity and Clinical Outcomes

Conditions
-----------------
Heart Failure, Implantable Defibrillator User, Ventricular Arrythmia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: records of systolic heart failure patients with primary prevention ICDs/CRT-Ds implanted for routine clinical indications Exclusion Criteria: absent baseline pre-implant digital ECG; missing data on clinical predictors and covariates; missing ICD programming data (including number of intervals to detect [NID] or time to detect, number of detection zones, heart rate for each detection zone, and anti-tachycardia pacing [ATP] programming); missing outcomes data. records of patients with inherited channelopathies (e.g. long QT syndrome, Brugada syndrome), inherited cardiomyopathies (e.g. hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy), and congenital heart disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary outcome: sustained VT/VF event with appropriate ICD therapy (either ATP or shock) | Sustained ventricular tachyarrhythmia event with appropriate ICD therapy (either antitachycardia pacing or shock) | up to 15 years | 
| Primary competing outcome: All-cause death without preceding sustained VT/VF with appropriate ICD therapy | All-cause death without preceding sustained ventricular tachyarrhythmia with appropriate ICD therapy | up to 15 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sustained monomorphic ventricular tachycardia | Sustained monomorphic ventricular tachycardia with appropriate ICD therapies (either antitachycardia pacing or ICD shock) | up to 15 years | 
| sustained polymorphic ventricular tachycardia / ventricular fibrillation | sustained polymorphic ventricular tachycardia or ventricular fibrillation with appropriate ICD therapies (either antitachycardia pacing or ICD shock) | up to 15 years |
Emergency Department Patient Satisfaction Survey in the Imam Reza Hospital , Tabriz ,Iran, 2008

Study Overview
=================
Brief Summary
-----------------
The investigators want to survey Emergency Department Patient Satisfaction in the Imam Reza hospital ,Tabriz ,Iran by questionnaire form . Finally the investigators want to improve the quality services in the department based on the research result.

Conditions
-----------------
Community Sample

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients admitted to emergency department Exclusion Criteria: patients didn't sign consent form
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient Satisfaction with nursing care<br> | |
| satisfaction of waiting time for first time visit<br> | |
| patient satisfaction<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Satisfaction |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patient Satisfaction
Access to Infertility Services: Clinic Perspective

Study Overview
=================
Brief Summary
-----------------
Since the identification of the human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome (AIDS) in the 1980s, there have been significant advances made in the management and long-term prognosis for infected individuals. Currently, with the advent of highly active antiretroviral therapy (HAART), HIV-positive individuals may live a healthy and productive life for years to decades after diagnosis. As life expectancy has increased, this group of people has begun to engage in family planning. This has created a need for access to advanced reproductive technologies and fertility treatments. While attempting to achieve pregnancy, utilization of these services can help to minimize the risk of transmission in serodiscordant couples, and can allow treatment of subfertile couples. Access to these services may be limited in Ontario for a variety of reasons. The purpose of this study is to determine the access to infertility clinics and services in Ontario for couples in which one or both partners is infected with HIV.

Official Title
-----------------
Access to Infertility Services in Ontario for Couples in Which One or Both Partners is HIV-Positive

Conditions
-----------------
Infertility

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All Ontario clinics offering advanced reproductive/infertility services Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infertility Services, HIV, pregnancy planning
Evaluation of Mild TBI in Collegiate Athletes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate blood-based biomarkers before and after sports-induced concussion using neuroimaging and head impact sensor technology.

Official Title
-----------------
AWARE: Mild Traumatic Brain Injury in Collegiate Athletes - A Prospective Study With Blood-based Biomarkers, Advanced Neuroimaging and the Head Impact Telemetry System (HITS)

Conditions
-----------------
Traumatic Brain Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: University of Florida student athlete involved in Men's Football, Men and Women's Basketball, Men and Women's Swimming, Men and Women's Diving, Women's Soccer, or Women's Lacrosse or University of Florida student athlete not participating in those sports who is being treated for a sports-related head injury. Age greater than or equal to 18 years of age. Willing to undergo the Informed Consent Process and provide Informed Consent prior to enrollment into the study. Exclusion Criteria: Subject is otherwise determined by the Investigator to be medically unsuitable for participation in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sports induced concussion<br>Exposure to sports induced concussion | |
| Routine Athletic Exertion<br>Exposure to routine athletic exertion without sports-induced concussion (non-concussion control) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of serum biomarker levels with neuroanatomic and neuropathologic changes from baseline using neuroimaging, following sports-related concussion |  | Baseline and up to 48 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of serum biomarker levels with head acceleration data using head impact telemetry system following sports-related concussion |  | Baseline and up to 48 months | 
| Correlation of serum biomarker levels and neuroimaging results to standard clinical measures of concussion in the acute phase of injury and at the completion of collegiate athletic participation |  | Baseline and up to 48 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
traumatic brain injury, sports head injury, sports concussion
Gut Hormones After Meal Ingestion in Males Versus Females

Study Overview
=================
Brief Summary
-----------------
The study hypothesis is that the release of gut hormones is increased proportionally to caloric load in each meal. Three different meals with different meal size will therefore be served and gut hormones determined.

Detailed Description
-----------------
In healthy males and females, meals with 511, 743 and 1034 kcal will be given orally. Samples will be taken during the following 300 min and gut hormones (glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1) will be determined along with insulin and glucagon levels.

Official Title
-----------------
Effects of Varying Meal Size on Gut Hormone and Islet Hormone Secretion in Males Versus Females

Conditions
-----------------
Normal Non-fluency

Intervention / Treatment
-----------------
* Other: Meal ingestion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy status Exclusion Criteria: Diabetes Liver disease kidney disease thyroid disease

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Healthy males<br>Meal ingestion in healthy males | Other: Meal ingestion<br>* Meal 511 kcal, meal 743 kcal or meal 1034 kcal<br>|
| Experimental: Healthy females<br>Meal ingestion in healthy females | Other: Meal ingestion<br>* Meal 511 kcal, meal 743 kcal or meal 1034 kcal<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Release of gut hormones |  | 300 min | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin secretion |  | 300 min | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gut hormones, Insulin secretion
Assessment of Brain Activities in Cervical Dystonia

Study Overview
=================
Brief Summary
-----------------
To address joint position sense in cervical dystonia patients and how it affects the brain activity.

Official Title
-----------------
Assessment of Cortical Network Activities in Cervical Dystonia

Conditions
-----------------
Cervical Dystonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients having cervical dystonia and aged matched healthy control group Exclusion Criteria: cervical dystonia patients with severe head tremor will be excluded

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 78 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cervical Dystonia<br>patients will have Cervical Dystonia | |
| Healthy control<br>Healthy Volunteers | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hand Joint Position Sense |  | 30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Brain Signals Recorded via Non-Invasive Surface Electromyography |  | 2 hours |
Overnight Pain Treatment Investigating Opioids vs. Nonopioids

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare maximum pain scores between patients seeking induced abortion and requiring cervical preparation with osmotic dilators. Patients will be randomized to receive prescription for ibuprofen alone or to receive prescription for ibuprofen + oxycodone for overnight pain management after cervical preparation with osmotic dilators. Data collected in-person and through a text-messaging platform.

Official Title
-----------------
A Pilot Randomized Trial of Opioids Versus Nonopioids for Pain Control After Osmotic Dilator Placement for Abortion Care

Conditions
-----------------
Abortion Second Trimester

Intervention / Treatment
-----------------
* Drug: Ibuprofen 600 mg
* Drug: OxyCODONE 5 Mg Oral Tablet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: English-speaking women 18 years or older Access to cell phone with text-messaging capability/data Receiving cervical preparation for induced abortion Able to complete baseline survey on smartphone/tablet at screening visit Exclusion Criteria: History of opioid or alcohol abuse Contraindications or allergy to ibuprofen Contraindications or allergy opioid medications Seeking uterine evacuation for premature preterm rupture of membranes or advanced - cervical dilation or intrauterine fetal demise

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Ibuprofen<br> | Drug: Ibuprofen 600 mg<br>* Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.<br>|
| Active Comparator: Ibuprofen + Oxycodone<br> | Drug: Ibuprofen 600 mg<br>* Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.<br>Drug: OxyCODONE 5 Mg Oral Tablet<br>* Oxycodone 5mg Oral Tablet prescription, to be taken 1-2 tablets as needed every 6 hours for pain.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum Pain Score | Numerical Rating Scale (NRS) pain score (scale range 0-10, with a 0 meaning no pain and 10 meaning the worst possible pain) | 24 hours |
Erector Spinae Plane Block Analgesia for Lumbar Spine Fusion Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to investigate the effect of a bilateral ultrasound guided erector spinae plane block on the pain scores and opoid utiliziation in fusion surgery of the lumbar spine.

Official Title
-----------------
Can Bilateral Erector Spinae Plane Block Minimize Perioprative Opioid Consumption and Provide Satisfactory Analgesia for Lumbar Spine Fusion Surgery? A Randomized Controlled Study

Conditions
-----------------
Pain, Postoperative

Intervention / Treatment
-----------------
* Drug: Erector spinae plane block
* Drug: sham subcutaneous infiltration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists class I-III adult patients BMI less than or equal 35 kg/m2 Exclusion Criteria: Patient refusal unable to give consent age < 18 or > 65 BMI more than 35 kg/m2 known allergy to the study medication coagulopathies or on anticoagulant medications hepatic insufficiency renal insufficiency chronic opioid use

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Erector block<br> | Drug: Erector spinae plane block<br>* bilateral ESP block will be injected with 20 ml of 0.25% bupivacaine<br>|
| Active Comparator: sham block<br> | Drug: sham subcutaneous infiltration<br>* bilateral ESP block will be injected with 20 ml of normal saline<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analgesia | Numerical rating scale of pain every 6 hours | Up to 24 hours after surgery |
Metformin for Weight Loss in Schizophrenia

Study Overview
=================
Brief Summary
-----------------
Study hypothesis is that patients on antipsychotics medication treated with metformin will show loss in weight and improved measures of glucose metabolism.

Detailed Description
-----------------
Patients who had gained more than 10 lbs of weight in the last 3 months or had BMI of 35 or greater were treated with metformin up to 2500 mg/day in an open label study of up to 3 months time. Changes in weight and glucose measures were recorded.

Official Title
-----------------
Evaluation of the Efficacy of Metformin for Weight Loss and Metabolic Effects In Overweight Psychiatric Patients Treated With Antipsychotic Medication

Conditions
-----------------
Schizophrenia, Obesity

Intervention / Treatment
-----------------
* Drug: Metformin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients will be 18-70 years of age; Currently hospitalized or an outpatient at MPC; BMI ≥ 35 or excessive recent weight gain ( > than 10 lb weight gain in the past 3 months); Patients will have a diagnosis of schizophrenia or schizoaffective disorder or bipolar disorder. Exclusion Criteria: Age below 18 or over 70; Patient is currently already treated with metformin.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Metformin<br> | Drug: Metformin<br>* metformin 500- 2500 mg/day. Patient received variable doses of metformin starting at 500 mg/day and increasing up to maximum of 2500 mg/day over 3-4 weeks. Dose was titrated on tolerability and side effects, especially development of hypoglycemia. This explains why different patients received different maximum doses.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight (wt) in Pounds (Lbs).. | Patients weight in pounds | baseline, 4 weeks, 8 weeks, 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose Levels | Fasting glucose | baseline, 4 weeks, 8 weeks, 12 weeks | 
| Insulin Level | fasting serum insulin uIU/ml. | baseline, 4 weks, 8 weeks, 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
schizophrenia, antipsychotics, obesity, diabetes
Prognosis in Patients With Chronic Respiratory Failure Receiving Domiciliary Noninvasive Positive Pressure Ventilation (NPPV)

Study Overview
=================
Brief Summary
-----------------
The purposes of the present study are (1) to analyze baseline patient characteristics cross-sectionally, (2) to analyze the prognosis and its predictive factors, and (3) to examine longitudinal clinical course in patients with chronic respiratory failure receiving domiciliary NPPV.

Detailed Description
-----------------
Limited data are available about the prognosis and its predictive factors in patients with chronic respiratory failure receiving domiciliary NPPV. In addition, their health status, psychological status and sleep quality seem to be highly disturbed due to severe respiratory insufficiency. Therefore, in the present study, we aim to examine (1) contributive factors to health status based on baseline data, (2) whether patient reported measurements such as health status, dyspnea and psychological status would predict patient's future outcomes, and (3) how they would change for 3 years as compared to physiological measurements.

Official Title
-----------------
Analysis of the Prognosis and Clinical Course in Patients With Chronic Respiratory Failure Receiving Domiciliary NPPV

Conditions
-----------------
Chronic Respiratory Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with chronic respiratory failure receiving domiciliary NPPV for more than 3 months Exclusion Criteria: Uncontrolled severe comorbidities Patients with tracheotomy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| NPPV<br>Patients with chronic respiratory failure receiving domiciliary NPPV | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prognosis/Mortality |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health status |  | At entry and every year for 3 years | 
| Dyspnea |  | At entry and every year for 3 years | 
| Psychological status |  | At entry and every year for 3 years | 
| Sleep quality |  | At entry and every year for 3 years | 
| Pulmonary function |  | At entry and every year for 3 years | 
| Arterial blood gas |  | At entry and every year for 3 years | 
| 6 minute walking tests |  | At entry and every year for 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NPPV, Prognosis, Health-related quality of life, Patient reported outcomes